163 related articles for article (PubMed ID: 27591000)
1. The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer.
Harrow S; Hanna GG; Faivre-Finn C; McDonald F; Chalmers AJ
Clin Oncol (R Coll Radiol); 2016 Nov; 28(11):720-725. PubMed ID: 27591000
[TBL] [Abstract][Full Text] [Related]
2. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.
Salama JK; Vokes EE
J Clin Oncol; 2013 Mar; 31(8):1029-38. PubMed ID: 23401449
[TBL] [Abstract][Full Text] [Related]
3. [Radiochemotherapy in non-small-cell lung cancer].
Swartman B
Med Klin Intensivmed Notfmed; 2011 Nov; 106(3):212-7. PubMed ID: 22068757
[No Abstract] [Full Text] [Related]
4. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer.
Yamaguchi M; Hirata H; Ebi N; Araki J; Seto T; Maruyama R; Akamine S; Inoue Y; Semba H; Sasaki J; Okamoto T
Jpn J Clin Oncol; 2020 Mar; 50(3):318-324. PubMed ID: 31804689
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
7. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
Feng J; Zhang S; Wu K; Wang B; Wong JY; Jiang H; Xu R; Ying L; Huang H; Zheng X; Chen X; Ma S
Mol Cancer Ther; 2016 May; 15(5):842-53. PubMed ID: 26839308
[TBL] [Abstract][Full Text] [Related]
8. Platinum derivatives alone, a reasonable option to treat locally advanced non-small cell lung cancer with chemo-radiotherapy.
Sanz Rubiales Á; del Valle Rivero ML; Fiorini Talavera AB; Fernández González M
Lung Cancer; 2015 Jul; 89(1):84-5. PubMed ID: 25982010
[No Abstract] [Full Text] [Related]
9. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis.
Chen Y; Peng X; Zhou Y; Xia K; Zhuang W
World J Surg Oncol; 2018 Jan; 16(1):8. PubMed ID: 29338734
[TBL] [Abstract][Full Text] [Related]
10. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
12. Emerging developments of chemoradiotherapy in stage III NSCLC.
Price A
Nat Rev Clin Oncol; 2012 Oct; 9(10):591-8. PubMed ID: 22926022
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of non-small cell lung cancer].
Hopstaken JS; de Ruiter JC; van Diessen JNA; Theelen WSME; Monkhorst K; Hartemink KJ
Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651512
[TBL] [Abstract][Full Text] [Related]
14. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.
Choy H; Gerber DE; Bradley JD; Iyengar P; Monberg M; Treat J; Govindan R; Koustensis A; Barker S; Obasaju C
Lung Cancer; 2015 Mar; 87(3):232-40. PubMed ID: 25650301
[TBL] [Abstract][Full Text] [Related]
15. Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy.
Morimoto M; Nishino K; Wada K; Imamura F; Konishi K; Kuhara H; Tamiya M; Inoue T; Kunimasa K; Kimura M; Hirata T; Kanayama N; Toratani M; Kawachi H; Ohira K; Nakanishi E; Ohira S; Sagawa T; Miyazaki M; Matsunaga T; Kumagai T; Teshima T
Anticancer Res; 2020 Dec; 40(12):6957-6970. PubMed ID: 33288590
[TBL] [Abstract][Full Text] [Related]
16. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
Huber RM; Reck M; Thomas M
Eur Respir J; 2013 Oct; 42(4):1119-33. PubMed ID: 23429914
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
Schild SE; Hillman SL; Tan AD; Ross HJ; McGinnis WL; Garces YA; Graham DL; Adjei AA; Jett JR;
J Thorac Oncol; 2017 Apr; 12(4):697-703. PubMed ID: 28089762
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
Zhang Q; Cai XW; Feng W; Yu W; Fu XL
BMC Cancer; 2022 Jan; 22(1):96. PubMed ID: 35065627
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
20. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
